Skip to main content
Journal cover image

Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.

Publication ,  Journal Article
Vaduganathan, M; Januzzi, JL
Published in: Am J Cardiol
December 15, 2019

Heart failure is a common complication among patients with type 2 diabetes mellitus and is associated with significantly increased risks of subsequent morbidity and mortality. Until recently, therapies and strategies were lacking to attenuate this excess risk of heart failure in this population. Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent a unique class of glucose-lowering therapies that have multisystem health benefits. Three large cardiovascular outcomes trials have demonstrated consistent reductions in heart failure events among patients with type 2 diabetes mellitus with, or at risk for, atherosclerotic cardiovascular disease. Another trial recently showed that an SGLT2 inhibitor, canagliflozin, also significantly reduced heart failure events among patients with type 2 diabetes mellitus and albuminuric chronic kidney disease. The SGLT2 inhibitor class represents an important new therapeutic approach for the prevention of heart failure in at-risk patients with type 2 diabetes mellitus, and is actively being studied for use in treating patients with heart failure (with or without type 2 diabetes mellitus). (Supplementary video "Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors" is available online.).

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

December 15, 2019

Volume

124 Suppl 1

Start / End Page

S20 / S27

Location

United States

Related Subject Headings

  • Sodium-Glucose Transporter 2 Inhibitors
  • Humans
  • Heart Failure
  • Diabetes Mellitus, Type 2
  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vaduganathan, M., & Januzzi, J. L. (2019). Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. Am J Cardiol, 124 Suppl 1, S20–S27. https://doi.org/10.1016/j.amjcard.2019.10.026
Vaduganathan, Muthiah, and James L. Januzzi. “Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.Am J Cardiol 124 Suppl 1 (December 15, 2019): S20–27. https://doi.org/10.1016/j.amjcard.2019.10.026.
Vaduganathan M, Januzzi JL. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. Am J Cardiol. 2019 Dec 15;124 Suppl 1:S20–7.
Vaduganathan, Muthiah, and James L. Januzzi. “Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.Am J Cardiol, vol. 124 Suppl 1, Dec. 2019, pp. S20–27. Pubmed, doi:10.1016/j.amjcard.2019.10.026.
Vaduganathan M, Januzzi JL. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. Am J Cardiol. 2019 Dec 15;124 Suppl 1:S20–S27.
Journal cover image

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

December 15, 2019

Volume

124 Suppl 1

Start / End Page

S20 / S27

Location

United States

Related Subject Headings

  • Sodium-Glucose Transporter 2 Inhibitors
  • Humans
  • Heart Failure
  • Diabetes Mellitus, Type 2
  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology